These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30077672)

  • 1. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
    Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
    Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical and Molecular Analyses Focusing on Mesenchymal Cells in Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis.
    Takada N; Mussazhanova Z; Hirokawa M; Nakashima M; Miyauchi A
    Pathobiology; 2018; 85(5-6):300-303. PubMed ID: 30223266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
    Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of cell-adhesion molecules in histological variants of papillary thyroid carcinoma.
    Andriescu EC; Căruntu ID; Giuşcă SE; Lozneanu L; Ciobanu Apostol DG
    Rom J Morphol Embryol; 2018; 59(3):721-727. PubMed ID: 30534810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases.
    Suster D; Michal M; Nishino M; Piana S; Bongiovanni M; Blatnik O; Hájková V; Ptáková N; Michal M; Suster S
    Mod Pathol; 2020 Sep; 33(9):1702-1711. PubMed ID: 32291398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.
    Šelemetjev S; Bartolome A; Išić Denčić T; Đorić I; Paunović I; Tatić S; Cvejić D
    Int J Exp Pathol; 2018 Apr; 99(2):87-94. PubMed ID: 29665129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological significance of epidermal growth factor receptor expression in papillary thyroid carcinoma: a meta-analysis.
    Qin XR; Huang JK; Yin QF; Shi XM; Tang JC; Hao LL; Li PF; Zhu J; Wang YX
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):175-181. PubMed ID: 33435649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
    Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
    J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.
    Ahn HY; Song RY; Ahn HS; Kim HS
    Cancer Res Treat; 2021 Oct; 53(4):1204-1212. PubMed ID: 33592140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
    Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
    Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
    Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
    J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage.
    Chen BK; Ohtsuki Y; Furihata M; Takeuchi T; Iwata J; Liang SB; Sonobe H
    Int J Oncol; 1999 Nov; 15(5):893-8. PubMed ID: 10536170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
    Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
    [No Abstract]   [Full Text] [Related]  

  • 20. SOX11 expression in a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma containing BRAF c.1799_1801delTGA and CTNNB1 c.133T>C mutations.
    Wong SBJ; Nga ME; Michal M; Vanecek T; Seet JE; Petersson F
    Virchows Arch; 2019 Oct; 475(4):519-525. PubMed ID: 31327063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.